- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Suven Life Sciences Limited — Updates, 03-09-2026: Press Release
03-09-2026 | 11:56 am
03-09-2026 | 11:56 am
Suven Life Sciences completed patient enrollment for its global Phase-3 Masupirdine study (SUVN-502) for Alzheimer’s Dementia agitation. 424 patients were randomized. Topline results are anticipated by May 2027, signaling progress in its CNS pipeline.
No comments yet. Be the first to comment!